MinervaX

Danish biotech MinervaX has launched the first Phase I clinical study in older adults of its novel Group B Streptococcus (GBS) vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is a global unmet medical burden and can cause serious illness in people of all ages, worldwide. It is normally associated with infection in […]